Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.533 | uM | 12523.164 | 0.7085 | 0.3157 | 0.8230 | |
| HCC1569 | HER2amp | Basal A | Everolimus | MTOR | MTOR | 2.67 | uM | 12523.164 | 0.7320 | 0.3690 | 0.8230 | |
| HCC1569 | HER2amp | Basal A | Everolimus | MTOR | MTOR | 13.3 | uM | 12523.164 | 0.6713 | 0.2323 | 0.8230 | |
| HCC1569 | HER2amp | Basal A | Everolimus | MTOR | MTOR | 66.7 | uM | 12523.164 | 0.1932 | -0.7287 | 0.8230 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000171 | uM | 12239.164 | 0.9533 | 0.9518 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000853 | uM | 12239.164 | 0.9777 | 0.9771 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.00427 | uM | 12239.164 | 1.0623 | 1.0625 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.0213 | uM | 12239.164 | 0.9229 | 0.9200 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.107 | uM | 12239.164 | 0.8836 | 0.8779 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.533 | uM | 12239.164 | 0.8612 | 0.8534 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 2.67 | uM | 12239.164 | 0.8160 | 0.8033 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 13.3 | uM | 12239.164 | 0.8166 | 0.8039 | 1.9638 | |
| HCC1806 | TNBC | Basal A | Everolimus | MTOR | MTOR | 66.7 | uM | 12239.164 | 0.7865 | 0.7698 | 1.9638 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000171 | uM | 11849.156 | 1.1151 | 1.2115 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000853 | uM | 11849.156 | 1.0523 | 1.0963 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.00427 | uM | 11849.156 | 0.9072 | 0.8280 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.0213 | uM | 11849.156 | 0.8772 | 0.7722 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.107 | uM | 11849.156 | 0.7279 | 0.4919 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.533 | uM | 11849.156 | 0.7016 | 0.4421 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 2.67 | uM | 11849.156 | 0.7061 | 0.4505 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 13.3 | uM | 11849.156 | 0.6818 | 0.4044 | 1.0836 | |
| HCC1937 | TNBC | Basal A | Everolimus | MTOR | MTOR | 66.7 | uM | 11849.156 | 0.0652 | -0.8391 | 1.0836 | |
| HCC1954 | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.000171 | uM | 11055.156 | 1.1065 | 1.1368 | 1.5301 | |
| HCC1954 | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.000853 | uM | 11055.156 | 1.0582 | 1.0753 | 1.5301 | |
| HCC1954 | HER2amp | Basal A | Everolimus | MTOR | MTOR | 0.00427 | uM | 11055.156 | 0.8356 | 0.7784 | 1.5301 |